Tango Therapeutics Hits New 52-Week High of $34.37, Up 351%

Tango Therapeutics, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 34.37 on June 17, 2026. This achievement marks a remarkable 350.98% increase in the stock's performance over the past year, significantly outpacing the S&P 500, which has seen a gain of 24.03% during the same period. With a market capitalization of USD 2,748 million, Tango Therapeutics operates in a competitive industry characterized by innovation and rapid advancements. Despite its recent stock performance, the company remains in a loss-making position, as indicated by its negative price-to-earnings ratio and return on equity of -29.35%. The stock's price-to-book ratio stands at 7.94, reflecting investor sentiment and valuation metrics. As Tango Therapeutics continues to navigate the dynamic landscape of pharmaceuticals and biotechnology, its recent price achievement underscores the company's notable progress within the market.